Midostaurin

Myelodysplastic Syndrome

National Cancer Institute (NCI)Small moleculePhase 2/3Active

B

61/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 55/ 100
Competitive Position: 73/ 100

Competitive context

295 Active assets in the Myelodysplastic Syndrome cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Nivestim City of Hope Medical Center	Phase 4	BB
Busulfanum Sawa Ito, MD	Phase 4	BB
Daunomycin OHSU Knight Cancer Institute	Phase 3	BB
Cytarabine The First Affiliated Hospital of Soochow University	Phase 4	BB

View all 50 →

Same molecule, other indications

Midostaurin is also rated in:

acute myeloid leukemia by FAB classificationActive

B

Indicative · Phase 2

63 / 100

acute myeloid leukemiaActive

B

Indicative · Phase 3

62 / 100

myelodysplastic syndrome with excess blasts-2Active

B

Indicative · Phase 3

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.